Financial Contrast: Nabriva Therapeutics AG (NBRV) and Its Peers
Nabriva Therapeutics AG (NASDAQ: NBRV) is one of 198 public companies in the “Biotechnology & Medical Research” industry, but how does it weigh in compared to its competitors? We will compare Nabriva Therapeutics AG to related companies based on the strength of its profitability, valuation, analyst recommendations, risk, dividends, earnings and institutional ownership.
Valuation and Earnings
This table compares Nabriva Therapeutics AG and its competitors gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|Nabriva Therapeutics AG||$6.01 million||-$59.30 million||-2.58|
|Nabriva Therapeutics AG Competitors||$207.78 million||-$2.31 million||0.68|
Nabriva Therapeutics AG’s competitors have higher revenue and earnings than Nabriva Therapeutics AG. Nabriva Therapeutics AG is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
Volatility & Risk
Nabriva Therapeutics AG has a beta of 1.66, meaning that its stock price is 66% more volatile than the S&P 500. Comparatively, Nabriva Therapeutics AG’s competitors have a beta of 1.63, meaning that their average stock price is 63% more volatile than the S&P 500.
This is a breakdown of current recommendations and price targets for Nabriva Therapeutics AG and its competitors, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Nabriva Therapeutics AG||0||0||7||0||3.00|
|Nabriva Therapeutics AG Competitors||476||2259||6167||119||2.66|
Nabriva Therapeutics AG presently has a consensus price target of $20.14, indicating a potential upside of 218.21%. As a group, “Biotechnology & Medical Research” companies have a potential upside of 13.35%. Given Nabriva Therapeutics AG’s stronger consensus rating and higher possible upside, equities analysts plainly believe Nabriva Therapeutics AG is more favorable than its competitors.
Institutional and Insider Ownership
50.2% of Nabriva Therapeutics AG shares are held by institutional investors. Comparatively, 46.7% of shares of all “Biotechnology & Medical Research” companies are held by institutional investors. 2.8% of Nabriva Therapeutics AG shares are held by company insiders. Comparatively, 13.8% of shares of all “Biotechnology & Medical Research” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
This table compares Nabriva Therapeutics AG and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Nabriva Therapeutics AG||N/A||-90.54%||-72.82%|
|Nabriva Therapeutics AG Competitors||-3,965.85%||-118.54%||-43.71%|
Nabriva Therapeutics AG beats its competitors on 7 of the 12 factors compared.
About Nabriva Therapeutics AG
Nabriva Therapeutics plc is a clinical stage biopharmaceutical company. The Company is engaged in engaged in the research and development of novel anti-infectives to treat serious infections, with a focus on the pleuromutilin class of antibiotics. The Company’s medicinal chemistry has enabled targeted discovery of novel pleuromutilins, including both intravenous and oral formulations of its lead product candidate, lefamulin. Lefamulin is a novel semi-synthetic pleuromutilin antibiotic with the potential to be the first-in-class available for systemic administration in humans. Lefamulin is being evaluated in two global, registrational Phase III clinical trials in patients with moderate to severe community-acquired bacterial pneumonia (CABP).It seeks to further pursue development of lefamulin for additional indications, including the treatment of acute bacterial skin and skin structure infections (ABSSSI), and is developing a formulation of lefamulin appropriate for pediatric use.
Receive News & Ratings for Nabriva Therapeutics AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nabriva Therapeutics AG and related companies with MarketBeat.com's FREE daily email newsletter.